title: Subjective Well-Being Under Neuroleptics Scale short form (SWN-K): reliability and validity in an Estonian speaking sample.
abstract: BACKGROUND
  The Subjective Well-Being Under Neuroleptic Treatment Scale short form (SWN-K) is a self-rating scale developed to measure mentally ill patients' well-being under the antipsychotic drug treatment. This paper reports on adaptation and psychometric properties of the instrument in an Estonian psychiatric sample.
  
  
  METHODS
  In a naturalistic study design, 124 inpatients or outpatients suffering from the first psychotic episode or chronic psychotic illness completed the translated SWN-K instrument. Item content analysis, internal consistency analysis, exploratory principal components analysis, and confirmatory factor analysis were used to construct the Estonian version of the SWN-K (SWN-K-E). Additionally, socio-demographic and clinical data, observer-rated psychopathology, medication side effects, daily antipsychotic drug dosages, and general functioning were assessed at two time points, at baseline and after a 29-week period; the associations of the SWN-K-E scores with these variables were explored.
  
  
  RESULTS
  After having selected 20 items for the Estonian adaptation, the internal consistency of the total SWN-K-E was 0.93 and the subscale consistencies ranged from 0.70 to 0.80. Good test-retest reliabilities were observed for the adapted scale scores, with the correlation of the total score over about 6 months being r = 0.70. Confirmatory factor analysis replicated the presence of a higher-order factor (general well-being) and five first-order factors (mental functioning, physical functioning, social integration, emotional regulation, and self-control); the model fitted the data well. The results indicated a moderate-high correlations r = 0.54 between the SWN-K-E total score and the evaluation how satisfied patients were with their lives in generally. No significant correlations were found between the overall subjective well-being score and age, severity of the psychopathology, drug adverse effects, or prescribed drug dosage.
  
  
  CONCLUSIONS
  Taken together, the results demonstrated that the Estonian version of the SWN-K is a reliable and valid instrument with psychometric properties similar to the original English version. The potential uses of the scale in both research and clinical settings are considered.
authors.affiliation: Psychiatry Clinic of Tartu University Hospital, University of Tartu, Tartu, Estonia. Liina.Haring@kliinikum.ee.
authors.forename: Liina
authors.initials: L
authors.lastname: Haring
authors.forename: René
authors.initials: R
authors.lastname: Mõttus
authors.forename: Peeter
authors.initials: P
authors.lastname: Jaanson
authors.forename: Raine
authors.initials: R
authors.lastname: Pilli
authors.forename: Kairi
authors.initials: K
authors.lastname: Mägi
authors.forename: Eduard
authors.initials: E
authors.lastname: Maron
references.citation: Am J Psychiatry. 2010 Jun;167(6):686-93
references.pmid: 20360319
references.citation: Schizophr Res. 2000 Jun 16;43(2-3):135-45
references.pmid: 10858632
references.citation: Value Health. 2005 Mar-Apr;8(2):94-104
references.pmid: 15804318
references.citation: Acta Psychiatr Scand Suppl. 1970;212:11-9
references.pmid: 4917967
references.citation: Schizophr Res. 2002 Jul 1;56(1-2):37-46
references.pmid: 12084418
references.citation: Pharmacopsychiatry. 2008 Jul;41(4):125-8
references.pmid: 18651339
references.citation: Soc Sci Med. 2007 Aug;65(4):698-711
references.pmid: 17507129
references.citation: Psychol Bull. 1955 Jul;52(4):281-302
references.pmid: 13245896
references.citation: Qual Life Res. 2006 Sep;15(7):1191-202
references.pmid: 17004003
references.citation: Qual Life Res. 2002 Mar;11(2):135-44
references.pmid: 12018737
references.citation: Int Clin Psychopharmacol. 1995 Sep;10 Suppl 3:133-8
references.pmid: 8866775
references.citation: Psychiatr Rehabil J. 2007 Winter;30(3):219-22
references.pmid: 17269273
references.citation: Pharmacoeconomics. 1997 Jan;11(1):32-47
references.pmid: 10172917
references.citation: Schizophr Bull. 2000;26(3):557-64
references.pmid: 10993397
references.citation: Psychiatry Res. 2005 Dec 15;137(3):203-13
references.pmid: 16298428
references.citation: Annu Rev Psychol. 2003;54:403-25
references.pmid: 12172000
references.citation: Aust N Z J Psychiatry. 2011 Mar;45(3):182-92
references.pmid: 21438745
references.citation: Psychiatr Serv. 2003 Apr;54(4):565-7
references.pmid: 12663847
references.citation: J Psychopharmacol. 2006 Nov;20(6 Suppl):38-56
references.pmid: 17046986
references.citation: Qual Life Res. 1993 Oct;2(5):327-33
references.pmid: 8136797
references.citation: Acta Psychiatr Scand Suppl. 2005;(427):29-34
references.pmid: 15943008
references.citation: J Pers Soc Psychol. 2002 Apr;82(4):582-93
references.pmid: 11999925
references.citation: Int J Psychiatry Clin Pract. 2005;9(2):94-8
references.pmid: 24930789
references.citation: Psychol Psychother. 2004 Mar;77(Pt 1):19-33
references.pmid: 15025902
references.citation: Br J Psychiatry. 1989 May;154:672-6
references.pmid: 2574607
references.citation: Am J Psychiatry. 1996 Apr;153(4):497-502
references.pmid: 8599397
references.citation: Arch Gen Psychiatry. 1976 Jun;33(6):766-71
references.pmid: 938196
references.citation: Schizophr Res. 2001 May 30;50(1-2):79-88
references.pmid: 11378316
references.citation: Qual Life Res. 2012 Aug;21(6):1075-84
references.pmid: 21964946
references.citation: Br J Psychiatry. 1992 Dec;161:797-801
references.pmid: 1483165
references.citation: Psychiatry Res. 2012 May 30;197(3):199-205
references.pmid: 22370148
references.citation: J Pers Soc Psychol. 2005 Sep;89(3):395-406
references.pmid: 16248721
references.citation: Qual Life Res. 2012 Jun;21(5):837-47
references.pmid: 21912845